Tab diltiazem for SVT
Reading File
Now let me search the medical library and PubMed in parallel.
Finding Sources
Finding Sources
Searching PubMed
diltiazem oral "supraventricular tachycardia"
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information. Here is a full summary of oral (tablet) diltiazem for SVT:
Diltiazem Tablets for SVT
Mechanism of Action
Diltiazem is a non-dihydropyridine calcium channel blocker that:
- Inhibits L-type calcium channels
- Slows AV nodal conduction
- Increases the AV node's refractory period
- Decreases automaticity
- Prolongs the PR interval
These effects make it effective for arrhythmias dependent on AV nodal conduction (e.g., AVNRT, AVRT) and for ventricular rate control in AF/flutter.
Indications for Oral Diltiazem in SVT
- Paroxysmal SVT (PSVT) - termination and prevention
- Rate control in AF/atrial flutter (most common use in practice)
- Transition from IV infusion once rate control is achieved in AF
Note: Verapamil is used more often than diltiazem for acute SVT termination (conversion rate ~90%, similar to adenosine), while diltiazem is more commonly used for rate control in AF.
Oral Dosing
Immediate-release (IR) tablets:
- Starting dose: 30-60 mg PO TID or QID (three to four times daily)
- Usual range: 120-360 mg/day in divided doses
- IR onset: 30-60 minutes, peak at 2-4 hours
Extended-release (ER) tablets:
- Once stable on IR, can transition to equivalent total daily dose given once or twice daily
- ER tablet onset: peak at 11-18 hours
Transitioning from IV to oral:
When transitioning from an IV infusion to oral:
- Use the IR formulation first
- Approximate conversion (Tintinalli's formula):
- IV infusion rate 10 mg/h → oral ~240 mg/day
- IV infusion rate 15 mg/h → oral ~360 mg/day
- Once stable on IR, switch to an equivalent ER formulation
Pharmacokinetics
| Parameter | IR Tablet | ER Tablet |
|---|---|---|
| Absorption | ~98% | ~93-95% |
| Oral bioavailability | ~40% (extensive first-pass) | ~40% |
| Protein binding | 70-80% | 70-80% |
| Metabolism | Hepatic (CYP450) | Hepatic (CYP450) |
| Half-life | 3-4.5 h | 6-9 h |
| Onset | 30-60 min | Longer |
| Peak | 2-4 h | 11-18 h |
Contraindications
- WPW syndrome / pre-excitation with SVT - HIGH RISK of life-threatening ventricular arrhythmia (blocks AV node, forcing conduction down accessory pathway)
- Wide-complex tachyarrhythmias (unless known SVT with aberrancy)
- Sick sinus syndrome (without pacemaker)
- 2nd or 3rd degree AV block (without pacemaker)
- Severe hypotension / cardiogenic shock
- Concurrent IV beta-blockers (risk of severe bradycardia/heart block)
- Ventricular tachycardia
Adverse Effects
- Bradycardia / bradyarrhythmia
- AV block
- Hypotension
- Peripheral edema
- Headache, dizziness, fatigue
- Syncope
- Asystole (rare)
Key Clinical Points
- Oral diltiazem is a secondary option for acute SVT - adenosine IV is first-line for acute termination; oral diltiazem is used for prevention of recurrence or rate control.
- Always rule out WPW before giving - a delta wave on baseline ECG or irregular, wide-complex AF should raise suspicion.
- Avoid combining with IV beta-blockers - serious bradycardia/heart block risk.
- Use IR first when starting orally; switch to ER once dose is established.
Sources: Tintinalli's Emergency Medicine, pp. 170-171; Katzung's Basic and Clinical Pharmacology 16e; Braunwald's Heart Disease
This is a shared conversation. Sign in to Orris to start your own chat.